Literature DB >> 26020523

Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report.

Volker Schirrmacher1, Wilfried Stücker1, Maria Lulei1, Akos-Sigmund Bihari1, Tobias Sprenger1.   

Abstract

Liver metastases in breast cancer are associated with a poor prognosis. We report long-term survival of a patient with breast cancer and liver metastases. After operation the patient declined further standard therapy. Instead, she was treated with local hyperthermia, Newcastle disease virus and dendritic cell vaccination at the Immunological and Oncological Center Cologne (IOZK), Germany. A continuous high quality of life was reported and the patient survived more than 66 months after initial diagnosis. No recurrence or further metastases developed under treatment. Following treatment, a long-lasting tumor-reactive memory T-cell responsiveness could be documented. This possibly explains the favorable course of disease. Since this combination of therapies is not restricted to a particular tumor type, further exploration is warranted.

Entities:  

Keywords:  Newcastle disease virus; breast cancer; dendritic cell vaccination; hyperthermia; immunotherapy

Mesh:

Year:  2015        PMID: 26020523     DOI: 10.2217/imt.15.48

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  11 in total

1.  Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.

Authors:  B Montico; C Lapenta; M Ravo; D Martorelli; E Muraro; B Zeng; E Comaro; M Spada; S Donati; S M Santini; R Tarallo; G Giurato; F Rizzo; A Weisz; F Belardelli; R Dolcetti; J Dal Col
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

Review 2.  Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field.

Authors:  Carrie Anne Minnaar; Andras Szasz
Journal:  Cells       Date:  2022-06-04       Impact factor: 7.666

3.  Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.

Authors:  Jochen Belmans; Matthias Van Woensel; Brecht Creyns; Joost Dejaegher; Dominique M Bullens; Stefaan W Van Gool
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

Review 4.  Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.

Authors:  Volker Schirrmacher
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

Review 5.  Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!

Authors:  Volker Schirrmacher
Journal:  Biomedicines       Date:  2016-07-20

Review 6.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

Review 7.  Modulated Electrohyperthermia: A New Hope for Cancer Patients.

Authors:  Huda F Alshaibi; Bashayr Al-Shehri; Basmah Hassan; Raghad Al-Zahrani; Taghreed Assiss
Journal:  Biomed Res Int       Date:  2020-11-13       Impact factor: 3.411

8.  Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.

Authors:  Volker Schirrmacher; Tobias Sprenger; Wilfried Stuecker; Stefaan W Van Gool
Journal:  Biomedicines       Date:  2020-07-23

Review 9.  Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.

Authors:  Qiuxing Meng; Jian He; Liping Zhong; Yongxiang Zhao
Journal:  Int J Med Sci       Date:  2021-03-30       Impact factor: 3.738

Review 10.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.